A mechanism-based group-psychotherapy approach to aggressive behaviour in borderline personality disorder: findings from a cluster-randomised controlled trial.
Group psychotherapy
anger regulation
dialectic behaviour therapy
emotional contagion
mentalisation-based therapy
threat hypersensitivity
Journal
BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931
Informations de publication
Date de publication:
14 Dec 2020
14 Dec 2020
Historique:
entrez:
14
12
2020
pubmed:
15
12
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Aggressive behaviour is a prevalent and harmful phenomenon in patients with borderline personality disorder (BPD). However, no short-term, low-cost programme exists that specifically focuses on aggression. Attuning therapy modules to pathogenetic mechanisms that underlie reactive aggression in BPD, we composed a 6 week mechanism-based anti-aggression psychotherapy (MAAP) approach for the group setting, which we tested against a non-specific supportive psychotherapy (NSSP). A cluster-randomised two-arm parallel-group phase II trial of N = 59 patients with BPD and overt aggressive behaviour was performed (German Registry for Clinical Trials, DRKS00009445). The primary outcome was the externally directed overt aggression score of the Modified Overt Aggression Scale (M-OAS) post-treatment (adjusted for pre-treatment overt aggression). Secondary outcomes were M-OAS irritability, M-OAS response rate and ecological momentary assessment of anger post-treatment and at 6 month follow-up, as well as M-OAS overt aggression score at follow-up. Although no significant difference in M-OAS overt aggression between treatments was found post-treatment (adjusted difference in mean 3.49 (95% CI -5.32 to 12.31, P = 0.22), the MAAP group showed a clinically relevant decrease in aggressive behaviour of 65% on average (versus 33% in the NSSP group), with particularly strong improvement among those with the highest baseline aggression. Most notably, significant differences in reduction in overt aggression between MAAP and NSSP were found at follow-up. Patients with BPD and aggressive behaviour benefited from a short group psychotherapy, with improvements particularly visible at 6 month follow-up. Further studies are required to show whether these effects are specific to MAAP.
Sections du résumé
BACKGROUND
BACKGROUND
Aggressive behaviour is a prevalent and harmful phenomenon in patients with borderline personality disorder (BPD). However, no short-term, low-cost programme exists that specifically focuses on aggression.
AIMS
OBJECTIVE
Attuning therapy modules to pathogenetic mechanisms that underlie reactive aggression in BPD, we composed a 6 week mechanism-based anti-aggression psychotherapy (MAAP) approach for the group setting, which we tested against a non-specific supportive psychotherapy (NSSP).
METHOD
METHODS
A cluster-randomised two-arm parallel-group phase II trial of N = 59 patients with BPD and overt aggressive behaviour was performed (German Registry for Clinical Trials, DRKS00009445). The primary outcome was the externally directed overt aggression score of the Modified Overt Aggression Scale (M-OAS) post-treatment (adjusted for pre-treatment overt aggression). Secondary outcomes were M-OAS irritability, M-OAS response rate and ecological momentary assessment of anger post-treatment and at 6 month follow-up, as well as M-OAS overt aggression score at follow-up.
RESULTS
RESULTS
Although no significant difference in M-OAS overt aggression between treatments was found post-treatment (adjusted difference in mean 3.49 (95% CI -5.32 to 12.31, P = 0.22), the MAAP group showed a clinically relevant decrease in aggressive behaviour of 65% on average (versus 33% in the NSSP group), with particularly strong improvement among those with the highest baseline aggression. Most notably, significant differences in reduction in overt aggression between MAAP and NSSP were found at follow-up.
CONCLUSIONS
CONCLUSIONS
Patients with BPD and aggressive behaviour benefited from a short group psychotherapy, with improvements particularly visible at 6 month follow-up. Further studies are required to show whether these effects are specific to MAAP.
Identifiants
pubmed: 33308363
doi: 10.1192/bjo.2020.131
pii: S2056472420001313
pmc: PMC7791567
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e17Références
J Pers Disord. 2003 Jun;17(3):233-42
pubmed: 12839102
J Neuropsychiatry Clin Neurosci. 1991 Spring;3(2):S44-51
pubmed: 1821222
Neuropsychopharmacology. 2003 Jun;28(6):1186-97
pubmed: 12700713
BMC Psychiatry. 2016 Aug 30;16:304
pubmed: 27577562
Psychiatry Res. 1997 Dec 5;73(3):147-57
pubmed: 9481806
J Abnorm Child Psychol. 2005 Jun;33(3):349-62
pubmed: 15957562
Acta Psychiatr Scand. 2009 Jul;120(1):53-61
pubmed: 19183126
Soc Neurosci. 2013;8(1):101-7
pubmed: 23327297
Acta Psychiatr Scand. 2011 May;123(5):327-38
pubmed: 21166785
Annu Rev Clin Psychol. 2007;3:1-27
pubmed: 17716046
J Pers Disord. 2009 Dec;23(6):541-54
pubmed: 20001173
JAMA Psychiatry. 2017 Apr 1;74(4):319-328
pubmed: 28249086
Psychopathology. 2018;51(2):76-82
pubmed: 29539627
J Pers Disord. 2004 Feb;18(1):36-51
pubmed: 15061343
Br J Psychiatry. 2017 Feb;210(2):149-156
pubmed: 27908900
Cogn Psychol. 2000 Aug;41(1):1-48
pubmed: 10945921
Philos Trans R Soc Lond B Biol Sci. 2018 Apr 19;373(1744):
pubmed: 29483341
J Abnorm Psychol. 2011 Aug;120(3):681-90
pubmed: 21500875
Br J Psychiatry. 2010 May;196(5):389-95
pubmed: 20435966
Clin Psychopharmacol Neurosci. 2019 Feb 28;17(1):43-53
pubmed: 30690939
JAMA Psychiatry. 2017 Aug 1;74(8):854-855
pubmed: 28636723
Psychotherapy (Chic). 2019 Jun;56(2):260-273
pubmed: 30869973
Am J Psychiatry. 2018 Aug 1;175(8):756-764
pubmed: 29621901
J Pers Disord. 2020 Feb;34(1):22-39
pubmed: 30355023
Personal Disord. 2018 Mar;9(2):172-181
pubmed: 27831693
Cochrane Database Syst Rev. 2010 Jun 16;(6):CD005653
pubmed: 20556762
J Psychiatr Pract. 2009 May;15(3):173-82
pubmed: 19461390
Personal Disord. 2015 Jul;6(3):278-91
pubmed: 26191822
Behav Res Ther. 2014 Aug;59:40-51
pubmed: 24974307
Personal Disord. 2015 Oct;6(4):347-55
pubmed: 26436578
J Clin Psychiatry. 2009 Apr 21;70(5):653-62
pubmed: 19389333
Trials. 2016 Nov 17;17(1):549
pubmed: 27855714
J Psychiatry Neurosci. 2018 Jan 12;43(2):170102
pubmed: 29336775
Am J Psychiatry. 2018 Dec 1;175(12):1265-1266
pubmed: 30501417
Behav Res Ther. 2010 Sep;48(9):832-9
pubmed: 20579633
J Pers Disord. 2017 Apr;31(2):256-272
pubmed: 27064852
Aggress Behav. 2014 Jul-Aug;40(4):329-36
pubmed: 24375428
Cochrane Database Syst Rev. 2020 May 4;5:CD012955
pubmed: 32368793
Aggress Behav. 2012 Sep-Oct;38(5):403-13
pubmed: 22711314
Behav Res Ther. 2009 May;47(5):353-8
pubmed: 19246029
Psychopathology. 2014;47(6):417-24
pubmed: 25378381